{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in PCT Patent Application No. PCT/US2011/040750 and foreign equivalents thereof entitled \"Agonistic Human Monoclonal Antibodies Against DR4\" (HHS Ref. No. E-158-2010/0) to Customized Biosciences, Inc., which is located in Pasadena, CA. The patent rights in these inventions have been assigned to the United States of America. The prospective start-up exclusive commercial license territory may be worldwide and the field of use may be limited to \"use of the Licensed Patent Rights to develop therapeutic agents for the treatment of lymphomas, leukemias, hepatocellular cancer, colorectal cancer, ovarian cancer, lung cancer, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease\".","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/02/01/2013-02152.html","cfr_references":[],"citation":"78 FR 7438","comment_url":null,"comments_close_on":"2013-02-19","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 19, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-02152","effective_on":null,"end_page":7438,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/02/01/2013-02152.xml","html_url":"https://www.federalregister.gov/documents/2013/02/01/2013-02152/prospective-grant-of-exclusive-license-development-of-human-monoclonal-antibodies-against-dr4","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-02152?publication_date=2013-02-01","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-02-01/2013-02152/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":73,"last_updated":"2026-07-28 12:15:07 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-02-01/pdf/2013-02152.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-02152.pdf?1359640843","publication_date":"2013-02-01","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/02/01/2013-02152.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-02-21T08:06:33Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":7438,"subtype":null,"title":"Prospective Grant of Exclusive License: Development of Human Monoclonal Antibodies Against DR4","toc_doc":"Development of Human Monoclonal Antibodies Against DR4","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":78}